ReviewFrontiers in endocrinology2026
Bioactive natural products predominantly derived from Chinese herbal medicines for diminished ovarian reserve: mechanistic insights into ovarian protection.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diminished ovarian reserve (DOR) is characterized by a reduction in oocyte quantity and quality and involves complex, interconnected pathological mechanisms. This review systematically evaluates bioactive natural products, predominantly derived from Chinese herbal medicines, using a mechanism-first framework, while considering their chemical scaffolds and botanical sources as complementary descriptors. Current evidence indicates that these compounds exert ovarian-protective effects through coordinated regulation of oxidative stress, inflammatory responses, DNA-damage repair and cellular senescence, apoptosis-related signaling, ferroptosis, and autophagy-mitophagy homeostasis. Across granulosa-cell systems and animal models of chemotherapy-induced ovarian injury, irradiation, accelerated aging, and reproductive aging, representative compounds have demonstrated beneficial effects on endocrine function, follicular preservation, mitochondrial homeostasis, oocyte quality, and fertility-related outcomes. Their capacity to modulate multiple interacting pathways may be particularly valuable for DOR, given its multifactorial pathogenesis. Emerging findings further suggest that the effects of apoptosis-, autophagy-, and growth-related signaling are dependent on cell type, pathway status, dose, timing, and disease stage, highlighting restoration of ovarian homeostasis as a central therapeutic principle. Although further studies incorporating rigorous causal validation, ovarian pharmacokinetic characterization, and standardized experimental design are warranted, the available evidence supports these natural products as promising candidates for mechanistic investigation and future therapeutic development in DOR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.